CANLI VERİCİLİ BÖBREK NAKLİ DONÖRLERİMİZİN UZUN DÖNEMLİ TAKİP SONUÇLARI

Giriş: Canlı vericili böbrek nakli, alıcı için mevcut faydalarıyla birlikte donörler için de artmış risk faktörleribarındırmaktadır. Biz bu çalışmamızda nakil amacıyla donör nefrektomi yapılan bireylerin uzun dönem takipsonuçlarını ortaya koymayı amaçladık.Gereç ve Yöntem: Ocak 1998 ile Haziran 2019 tarihleri arasında kliniğimizde gerçekleştirilen canlı vericili böbreknakillerine ait ve en az 1 yıl takip süresi olan 297 donör çalışmaya alındı. Veriler hasta dosyalarından retrospektifolarak kaydedildi. Son kontrolde donörlere ait klinik ve laboratuar özellikler bağış öncesi dönemle karşılaştırıldı.Ayrıca,donörler son kontroldeki GFR değerlerine göre iki gruba ayrılarak (Grup 1: GFR ˂ 60 mL/dk/1.73 m² ,Grup 2 : GFR ˃ 60 mL/dk/1.73 m² ) karşılaştırıldı.Bulgular: Donörlerin ortalama takip süresi 47,4±44,3[12-215] ay, ortalama yaşı 47.3 ± 11.4 yıldı. Kadın donörlerinsayısı 148 (49,8 %)di. Son kontrolde donörlere ait HT ve obezite oranı nefrektomi öncesi dönemlekarşılaştırıldığında anlamlı şekilde artış olduğu tespit edildi(6.3% vs 3.3%, 30.3% vs 21.5). Takip sırasında 79(26,6%) olguda GFR ˂ 60 mL/dk/1.73 m² (Grup 1) iken 218 (73,4%) olguda GFR ˃ 60 mL/dk/1.73 m² (Grup 2) idi.Gruplar karşılaştırıldığında 1. Gruptaki olguların daha yaşlı (52.3 ± 10 vs 45.5±11 yıl, p=0.001) ve nefrektomiöncesi dönemde daha yüksek hipertansif donör oranına( 6% vs 4%, p=0.01) ve bazal ürik asit seviyelerine sahip(5±1.4 vs 4.5±1.4, p=0.003) oldukları görüldü.Sonuç: Donör nefrektomi yapılan bireylerin uzun dönem takiplerinde HT ve obezite insidansı artış göstermektedir.GFR’de düşüş olmasına rağmen, son dönem böbrek yetmezliği (SDBY) riski düşüktür.

LONG-TERM FOLLOW-UP RESULTS OF OUR LIVING KIDNEY TRANSPLANTATION DONORS

Introduction: Living-donor kidney transplantation has increased risk factors for donors despite benefits for the recipients. In this study, we aimed to evaluate the long-term follow-up results of living kidney donors. Material and Method: Living donors of kidney transplants between January 1998 and June 2019 were retrospectively evaluated. 297 cases were included in the study. Donors with less than 1 year of follow-up were excluded. At the last control, the clinical and laboratory characteristics of the donors were compared with the predonation period. The participants were divided into to groups according to last control GFR value (Group 1: GFR ˂ 60 mL/dk/1.73 m², Group 2 : GFR ˃ 60 mL/dk/1.73 m² ). Results: In the included 297 donors, mean follow-up in months ± SD (range) was47,4±44,3[12-215]. The mean age in years ± SD (range) was47.3 ± 11.4 and 49,8 % of donors were female.At the last control, the hypertension(HT) and obesity rate of donors were found to be significantly increased compared to the prenephrectomy period (6.3% vs 3.3%, 30.3% vs 21.5). During follow-up, GFR was ˂ 60 mL / min / 1.73 m² (Group 94 İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi (Medical Journal of İzmir Hospital) 1) in 79 (26.6%) cases, and GFR was ˃ 60 mL / min / 1.73 m² (Group 2) in 218 (73.4%) cases. Compared with counterparts, the patients in the Group 1 were older (52.3 ± 10 vs 45.5 ± 11 years, p = 0.001) and had higher hypertension rate (6% vs 4%, p = 0.01) and basal uric acid levels in the pre-nephrectomy period (5 ± 1.4 vs 4.5 ± 1.4, p = 0.003). Conclusion: The incidence of HT and obesity has increased in the living kidney donors at the follow-up. Although there is a decrease in GFR, the risk of end stage renal failure (ESRD) is low.

PDF

___

1. Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE et al. Perioperative mortality and long-term survival following live kidney donation. Jama 2010; 303(10): 959-66.
2. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant 2002; 17(11): 2036-7.
3. Hartmann A, Fauchald P, Westlie L, Brekke IB, Holdaas H. The risk of living kidney donation. Nephrol Dial Transplant 2003; 18(5): 871-3.
4. Mjøen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Øyen O et al. Long-term risks for kidney donors. Kidney Int 2014; 86(1): 162-7.
5. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL et al. Risk of end-stage renal disease following live kidney donation. Jama 2014; 311(6): 579-86.
6. Lentine KL, Patel A. Risks and outcomes of living donation. Adv Chronic Kidney Dis 2012; 19(4): 220-8.
7. Hosokawa Y, Tanaka N, Mibu H, Anai S, Torimoto K, Yoneda T et al. Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume. World J Surg Oncol 2014; 12: 59.
8. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014; 63(5): 713-35.
9. Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tydén G, Groth CG. Kidney donors live longer. Transplantation 1997; 64(7): 976-8.
10. Li SS, Huang YM, Wang M, Shen J, Lin BJ, Sui Y et al. A meta-analysis of renal outcomes in living kidney donors. Medicine (Baltimore) 2016; 95(24): e3847.
11. Wainright JL, Robinson AM, Wilk AR, Klassen DK, Cherikh WS, Stewart DE. Risk of ESRD in prior living kidney donors. Am J Transplant 2018; 18(5): 1129-39.
12. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., Whelton PK et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144(3): 172-80.
13. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382(9888): 260-72.
14. O'Keeffe LM, Ramond A, Oliver-Williams C, Willeit P, Paige E, Trotter P et al. Mid- and Long-Term Health Risks in Living Kidney Donors: A Systematic Review and Meta-analysis. Ann Intern Med 2018; 168(4): 276-84.
15. Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol 2014; 2014: 852954.
16. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164(14): 1546-51.
17. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971- 1992. National Health and Nutrition Examination Survey. Jama 2000; 283(18): 2404-10.
18. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811-21.
19. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13(12): 2888-97.
20. Chou YC, Kuan JC, Yang T, Chou WY, Hsieh PC, Bai CH et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol 2015; 28(4): 457-62.
21. Garg AX, Prasad GV, Thiessen-Philbrook HR, Ping L, Melo M, Gibney EM et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation 2008; 86(3): 399- 406.
22. Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 2006; 145(3): 185-96.
23. Ibrahim HN, Foley RN, Reule SA, Spong R, Kukla A, Issa N et al. Renal Function Profile in White Kidney Donors: The First 4 Decades. J Am Soc Nephrol 2016; 27(9): 2885-93.
24. Potluri V, Harhay MN, Wilson FP, Bloom RD, Reese PP. Kidney transplant outcomes for prior living organ donors. J Am Soc Nephrol 2015; 26(5): 1188-94.